Want to join the conversation?
$PFE said it has published new analysis of data from 3 VYNDAQEL studies in patients with mild transthyretin familial amyloid polyneuropathy. The analysis showed that VYNDAQEL treatment during early disease stage resulted in minimal neurological disease progression and in preservation of body weight, which often declines as disease progresses.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?